MiRNA-20a targets TXNIP to inhibit the activation of NLRP3, ASC and caspase-1 in adjuvant-induced arthritis FLS and to suppress the secretion of IL-1 and MMP-1. This evidence concerns the gene NLRP3 and arthritic joint disease.